[1,2,4]Triazolo[1,5‐c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer Cell Lines

Abstract

AbstractThe A3 adenosine receptor is an interesting target whose role in cancer is controversial. In this work, a structural investigation at the 2‐position of the [1,2,4]triazolo[1,5‐c]pyrimidine nucleus was performed, finding new potent and selective A3 adenosine receptor antagonists such as the ethyl 2‐(4‐methoxyphenyl)‐5‐(methylamino)‐[1,2,4]triazolo[1,5‐c]pyrimidine‐8‐carboxylate (20, DZ123) that showed a Ki value of 0.47 nM and an exceptional selectivity profile over the other adenosine receptor subtypes. Computational studies were performed to rationalize the affinity and the selectivity profile of the tested compounds at the A3 adenosine receptor and the A1 and A2A adenosine receptors. Compound 20 was tested on both A3 adenosine receptor positive cell lines (CHO‐A3AR transfected, THP1 and HCT16) and on A3 negative cancer cell lines, showing no effect in the latter and a pro‐proliferative effect at a low concentration in the former. These interesting results pave the way to further investigation on both the mechanism involved and potential therapeutic applications.